NCT04420975
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 11 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 54 words Show 4 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Jan 31, 2027 to Nov 12, 2026
- Secondary endpoints: details revised at 2 of 2 entries
- Site details revised
- Notable Primary completion date: Jan 31, 2026 to Jan 31, 2027
- Study completion date: Jan 31, 2027 to Jan 31, 2028
- Notable Primary completion date: Jan 31, 2025 to Jan 31, 2026
- Study completion date: Jan 31, 2026 to Jan 31, 2027
- Start date: Oct 29, 2020 to Oct 14, 2020
- Notable Primary completion date: Jan 31, 2024 to Jan 31, 2025
- Study completion date: Jan 31, 2025 to Jan 31, 2026
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 20 to confirmed 14
- Site details revised
Show 5 earlier versionsHide 5 earlier versions
Notable Eligibility criteria expanded, about 35 wordsv6 Show 8 more changesShow less
- Primary endpoint revised
- Enrollment target: 25 to 20
- Start date: Oct 14, 2020 to Oct 29, 2020
- Interventions: Definitive Surgical Resection (Procedure), Immunotherapeutic Agent (Drug), Nivolumab (Biological), Radiation Therapy (Radiation) to Definitive Surgical Resection (Procedure), Nanoplexed Poly I:C BO-112 (Biological), Nivolumab (Biological), Radiation Therapy (Radiation)
- Secondary endpoints revised (2)
- Study description expanded, about 13 words
- Site contact updated
- Collaborators reordered
- Minor Collaborators expanded, about 6 wordsv5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 1, 2020 to Oct 14, 2020
- Site details revised
- Notable Start date: Jun 30, 2020 to Sep 1, 2020
- Collaborators shortened, about 4 words
- Minor Secondary endpoints: details revised at 2 of 2 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of adverse events (AEs)
Timeframe: study enrollment through 100 days after the last dose of study drug
Secondary (2)
Immune-oncologic impact of the BO-112 or the combined regimen of nivolumab and BO-112
Pathologic treatment effect
Arms and interventions
Treatment (BO-112, nivolumab)Experimental
Patients receive BO-112 intratumorally on days 8 and 15 or 1, 8, and 15 and nivolumab IV over 30-60 minutes on day 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.
Procedures: Definitive Surgical Resection
Biologicals: Nanoplexed Poly I:C BO-112, Nivolumab
Radiation: Radiation Therapy
Sites
1 site in 1 country
- UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, California, United States